Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Long-term oncological outcomes of robotic versus laparoscopic total mesorectal excision for rectal cancer: COLRAR randomized clinical trial.

Created on 26 Oct 2026

Authors

Seung Ho Song, Byung Soh Min, Jun Seok Park, Kang Young Lee, Nam Kyu Kim, Seon-Hahn Kim, Soo Yeun Park, Hye Jin Kim, Sung-Min Lee, Gyu-Seog Choi

Published in

The British journal of surgery. Volume 113. Issue 10. Oct 05, 2026.

Abstract

Long-term oncological equivalence of robotic total mesorectal excision (R-TME) and laparoscopic total mesorectal excision (L-TME) remains unproven. The 5-year outcomes of the COLRAR RCT are reported.
Adults with cT1-4a Nx M0 rectal adenocarcinoma within 10 cm of the anal verge were randomized 1 : 1 to L-TME or R-TME at three Korean tertiary centres between July 2011 and February 2016. Pre-specified secondary endpoints were 5-year overall, relapse-free, local recurrence-free, and distant recurrence-free survival. Analyses were on a modified intention-to-treat basis.
Of 295 analysed patients (144 L-TME patients and 151 R-TME patients; median follow-up of 72.6 months), 5-year overall survival (92.6% versus 92.4%; P = 0.838) and relapse-free survival (81.9% versus 83.0%; P = 0.801) were similar. Local recurrence occurred in 4.9% (L-TME) and 1.3% (R-TME); 5-year local recurrence-free and distant recurrence-free survival did not differ (P = 0.076 and P = 0.655). In a post-hoc analysis of 146 patients who received neoadjuvant chemoradiotherapy, 5-year local recurrence-free survival was 98.6% in R-TME patients versus 90.7% in L-TME patients (P = 0.039).
R-TME and L-TME produced equivalent 5-year oncological outcomes. A post-hoc analysis suggested improved local control with robotic surgery after neoadjuvant chemoradiotherapy, requiring confirmation in prospectively designed studies.
NCT01423214 (http://www.clinicaltrials.gov).

PMID:
42929021
Bibliographic data and abstract were imported from PubMed on 26 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement